# US 2023/0057788 A1 · Method of treating chronic myeloid leukemia using pegylated interferon and tyrosine kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057788 A1
- Document ID: US20230057788A1
- Status: Published application
- Kind: A1
- Application number: 17/882,087
- Filed: 2022-08-05
- Published: 2023-02-23
- Earliest claimed: 2021-08-05
- Assignees: PharmaEssentia Corp.
- Applicants: PharmaEssentia Corporation
- Inventors: Ko-Chung Lin
- Web page: https://patentgrep.com/patent/US20230057788A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein is a method of treating chronic myeloid leukemia in a subject including administering to a subject in need thereof a pegylated interferon-α and a BCR-ABL tyrosine kinase inhibitor simultaneously or sequentially.

## Claims

### Claim 1

A method of treating chronic myeloid leukemia in a subject, the method comprising administering to a subject in need thereof a pegylated interferon-α and a BCR-ABL tyrosine kinase inhibitor simultaneously or sequentially for a treatment period, wherein the pegylated interferon-α is a conjugate of formula I:
in which
each of R1, R2, R3, R4, and R5, independently, is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteraryl, C3-8 cycloalkyl, or C3-8 heterocycloalkyl;
each of A1 and A2, independently, is a polymer moiety;
each of G1, G2, and G3, independently, is a bond or a linking functional group;
P is an interferon-α moiety;
m is 0 or an integer of 1-10; and
n is an integer of 1-10.

### Claim 2 (depends on 1)

The method of claim 1, wherein the conjugate has one or more properties including:
(i) a median Tmax in the range of 3 to 6 days following administration of multiple 50 to 540 μg doses of the conjugate once every two weeks to subjects;
(ii) a mean T1/2 in the range of 6 to 10 days following administration of multiple 50 to 540 μg doses of the conjugate once every two weeks to subjects; and
(iii) an individual maximum tolerated dose of at least 500 μg once every 2 to 4 weeks in subjects.

### Claim 3 (depends on 1)

The method of claim 1, wherein the conjugate has one or more features including: G3 is a bond and P is an interferon-α moiety in which the amino group at the N-terminus is attached to G3; A1 and A2 are polyalkylene oxide moieties each having a molecular weight of 10-30 kD; each of G1 and G2 is
in which O is attached to A1 or A2, and NH is attached to a carbon atom as shown in formula I; each of R1, R2, R3, R4, and R5 is H; m is 4 and n is 2; and the interferon-α moiety is a modified interferon-α moiety containing 1-4 additional amino acid residues.

### Claim 4 (depends on 1)

The method of claim 1, wherein the interferon-α moiety is a human interferon-α2b having a proline residue at the N-terminus and is 166 amino acids in length.

### Claim 5 (depends on 1)

The method of claim 1, wherein the conjugate is
in which mPEG has a molecular weight of 20 kD and IFN is an interferon-α2b.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tyrosine kinase inhibitor is imatinib, dasatinib, nilotinib, bosutinib, or ponatinib.

### Claim 7 (depends on 6)

The method of claim 6, wherein 100 to 800 mg of imatinib is administered to the subject daily.

### Claim 8 (depends on 1)

The method of claim 1, wherein 50 to 540 μg of the pegylated interferon-α is administered to the subject once every 2 to 8 weeks.

### Claim 9 (depends on 8)

The method of claim 8, wherein 50 to 100 μg of the pegylated interferon is administered to the subject once every 2 weeks.

### Claim 10 (depends on 1)

The method of claim 1, wherein the treatment period is at least 6 months, at least 12 months, at least 18 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, or at least 54 months or more.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject was previously treated with imatinib or another BCR-ABL tyrosine kinase inhibitor alone, or an interferon or pegylated interferon alone.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is treated with the pegylated interferon-α and the BCR-ABL tyrosine kinase inhibitor sequentially.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is first treated with the BCR-ABL tyrosine kinase inhibitor alone followed by the pegylated interferon-α alone, or is first treated with the pegylated interferon-α alone followed by the BCR-ABL tyrosine kinase inhibitor alone.

### Claim 14 (depends on 1)

The method of claim 1 wherein the subject has a reduction of BCR-ABL1 transcript to at least ≤0.01% or deeper during or by end of the treatment period.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject has a reduction of BCR-ABL1 transcript to at least ≤0.0032% or deeper during or by the end of the treatment period.

### Claim 16 (depends on 14)

The method of claim 14, wherein the reduction is detected at 12 months or earlier in the treatment period.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject has a complete hematologic response or a cytogenetic response or both during or by end of the treatment period.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject has a complete cytogenic response.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject has a complete hematologic response and a complete cytogenetic response.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject has less adverse events or lower grade adverse events than a subject treated with a combination of a BCR-ABL tyrosine kinase inhibitor and another pegylated interferon.
